Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.
Vijayakrishna Gadi, MD, University of Illinois College of Medicine
Advertisement
Articles by Vijayakrishna Gadi, MD, University of Illinois College of Medicine
Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.
Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.
The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.
Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.
Decision Factors for SubQ Therapy and Unmet Needs
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Phase 3 FeDeriCa and PHranceSCa Trial Overviews
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Novel Agents for Late-Stage HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Practical Advice for Toxicity Management in HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Brain Metastases Therapy in Second-Line HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Sequencing Therapy in R/R HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Newly FDA Approved Therapies: R/R HER2+ MBC
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Moving Metastatic Therapy to Early Stage Setting
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Hormone Therapy in HER2+ Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
De-Escalation of Adjuvant Anti-HER2 Therapy and Chemo
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Adjuvant Systemic Therapy Data Updates
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Adjuvant Systemic Therapy Decision Factors
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
HR-/HER2+ Early Stage Breast Cancer: Standards of Care
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
Refining Treatment Approaches for HER2+ Breast Cancer
ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Lisa Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center,Vijayakrishna Gadi, MD, University of Illinois College of Medicine,William Gradishar, MD, Northwestern Medicine,Claudine Isaacs, MD, Lombardi Comprehensive Cancer Center
A discussion on systemic treatment for HER2+ breast cancer and the impact of recent clinical trial data on decision making, including data discussed at the ESMO and SABCS 2020 Annual Meetings.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5